Recently, Charles River Laboratories—a provider of products and services for drug research and development—presented a webinar about starting material for manufacturing cell therapies. Scott R. Burger ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...